Expertise in
26
conditions

Dr. Seema Nagpal

Neurology
300 Pasteur Dr, 
Stanford, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
26
conditions
300 Pasteur Dr, 
Stanford, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Seema Nagpal is a Neurologist in Stanford, California. Dr. Nagpal is highly rated in 26 conditions, according to our data. Her top areas of expertise are Brain Tumor, Astrocytoma, Glioblastoma, and Glioma.

Her clinical research consists of co-authoring 113 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in CA
Hospital Affiliations
Stanford Health Care
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Health Advantage
  • HMO
  • INSURANCE PLAN
  • MEDICARE DISCOUNT CARD
  • MEDICARE MAPD
View 7 Less Insurance Carriers -

Locations

STANFORD HEALTH CARE
300 Pasteur Dr, Stanford, CA 94305

Additional Areas of Focus

Dr. Nagpal has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma
A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma
Enrollment Status: Recruiting
Publish Date: June 27, 2025
Intervention Type: Procedure, Device, Biological
Study Phase: Phase 2
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Biological, Drug, Radiation
Study Drugs: INO-5401, INO-9012, Cemiplimab, Temozolomide
Study Phase: Phase 1/Phase 2
EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Phase I, First-In-Human, Multicenter, Open-Label Dose Escalation and Dose Expansion Study of ABM-1310, as a Monotherapy and a Combination Therapy, Administered Orally in Adult Patients With Advanced Solid Tumors Harboring BRAF Mutations
A Phase I, First-In-Human, Multicenter, Open-Label Dose Escalation and Dose Expansion Study of ABM-1310, as a Monotherapy and a Combination Therapy, Administered Orally in Adult Patients With Advanced Solid Tumors Harboring BRAF Mutations
Enrollment Status: Terminated
Publish Date: May 21, 2024
Intervention Type: Drug
Study Drug: ABM-1310
Study Phase: Phase 1
Assessment of Safety and Feasibility of Exablate Type 2 for Blood-Brain Barrier Disruption (BBBD) With Microbubble Resonators for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carboplatin Monotherapy
Assessment of Safety and Feasibility of Exablate Type 2 for Blood-Brain Barrier Disruption (BBBD) With Microbubble Resonators for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carboplatin Monotherapy
Enrollment Status: Active_not_recruiting
Publish Date: March 05, 2024
Intervention Type: Drug, Device
Study Drug: Carboplatin
Study Phase: Phase 1/Phase 2
A Phase I Study of BPM31510 Plus Vitamin K in Subjects With High-Grade Glioma That Has Recurred on a Bevacizumab Containing Regimen
A Phase I Study of BPM31510 Plus Vitamin K in Subjects With High-Grade Glioma That Has Recurred on a Bevacizumab Containing Regimen
Enrollment Status: Completed
Publish Date: August 10, 2021
Intervention Type: Drug, Other
Study Drug: Ubidecarenone
Study Phase: Phase 1
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN
Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN
Enrollment Status: Terminated
Publish Date: December 19, 2018
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: October 23, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 8 Less Clinical Trials

113 Total Publications

Repeat stereotactic radiosurgery for treatment of brain metastases locally recurrent following initial radiosurgery.
Repeat stereotactic radiosurgery for treatment of brain metastases locally recurrent following initial radiosurgery.
Journal: Journal of neuro-oncology
Published: July 07, 2025
Similar Doctors
Expertise in
42
conditions
Dr. Lawrence Recht
Neurology
Expertise in
42
conditions
Dr. Lawrence Recht
Neurology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (0.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lawrence Recht is a Neurologist in Stanford, California. Dr. Recht is highly rated in 42 conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Expertise in
73
conditions
Dr. Jacinda Sampson
Neurology
Expertise in
73
conditions
Dr. Jacinda Sampson
Neurology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (0.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jacinda Sampson is a Neurologist in Stanford, California. Dr. Sampson is highly rated in 73 conditions, according to our data. Her top areas of expertise are Oculodentodigital Dysplasia, Myotonic Dystrophy Type 2, Myotonic Dystrophy, Paramyotonia Congenita, and Thymectomy.

Expertise in
21
conditions
Dr. Kimford J. Meador
Neurology
Expertise in
21
conditions
Dr. Kimford J. Meador
Neurology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (0.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kimford Meador is a Neurologist in Stanford, California. Dr. Meador is highly rated in 21 conditions, according to our data. His top areas of expertise are Epilepsy, Seizures, Generalized Tonic-Clonic Seizure, Memory Loss, and Deep Brain Stimulation.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nagpal's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 12 Advanced Conditions
View All 36 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile